ArticleActa pharmaceutica Sinica. B2022

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.

Jie Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.